The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
- 1 April 1990
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 39 (4) , 403-409
- https://doi.org/10.1016/0026-0495(90)90256-c
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Gemfibrozil in the Treatment of Resistant Familial Hypercholesterolemia and Type III HyperlipoproteinaemiaJournal of the Royal Society of Medicine, 1988
- Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein BAtherosclerosis, 1988
- Effect of fenofibrate treatment on type III hyperlipoproteinemiaThe American Journal of Medicine, 1987
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group IIPublished by American Medical Association (AMA) ,1986
- Preliminary report: Treatment of type 3 hyperlipoproteinemia with mevinolinMetabolism, 1986
- Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemiaMetabolism, 1985
- A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemiaAtherosclerosis, 1985
- Treatment of type III hyperlipoproteinemia with four different treatment regimensAtherosclerosis, 1984
- The Biochemical, Clinical, and Genetic Features of Type III HyperlipoproteinemiaAnnals of Internal Medicine, 1975